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Abstract
Background: To estimate the need for bilateral intravitreal anti-VEGF injections in patients treated for neovascular
age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal
neovascularization (CNV) in high myopia, and other causes of CNV.
Methods: All consecutive patients treated with intravitreal anti-VEGF injection over a 1-month period were included in
a prospective multicenter survey. The reason for intravitreal anti-VEGF injection and the involvement of the fellow eye
in the pathology requiring a treatment with intravitreal anti-VEGF were recorded. A time interval between bilateral
injections longer than 1 month, within a 1-month period, and same-day bilateral injections were recorded.
Results: A total of 1335 patients were included, corresponding to 1024 (76.7 %) patients treated for nAMD, 167 (12.
5 %) for DME, and 144 (10.8 %) for other reasons. Four hundred and fifty-nine (34.4 %) patients were treated bilaterally
with a time interval between injections longer than 1 month, 170 (12.7 %) were treated bilaterally within a 1-month
interval, and 87 (6.6 %) had same-day bilateral injections. Bilateral injections were more frequent in diabetic patients
than in nAMD patients (respectively 48 % vs. 36 %, p = 0.0033).
Conclusions: Patients with DME are more likely to be treated bilaterally with anti-VEGF injections. As the rate of
second eye involvement requiring treatment increases progressively over time, a same-day bilateral injection strategy
will become more common as it decreases the administrative burden on the healthcare system and treatment burden
experienced by patients.
Keywords: Intravitreal injection, Age-related macular degeneration, Anti-VEGF, Diabetic macular edema, Retinal
diseases
Background
The number of intravitreal anti-VEGF injections has in-
creased progressively, partly because of the extension of
anti-VEGF indications to various chorioretinal diseases.
Anti-VEGFs have been first indicated for the treatment
of neovascular age-related macular degeneration (nAMD)
[1, 2], then macular edema complicating retinal vein occlu-
sion (RVO) [3–6], diabetic macular edema (DME) [7–9],
and other causes of choroidal neovascularization (CNV)
such as high myopia.
nAMD and DME frequently affect both eyes [10, 11].
The fellow eye involvement, which is often the better-
seeing eye, is likely to have a significant impact on pa-
tient quality of life.
Patients with nAMD require anti-VEGF treatment in
their fellow eye in about 7.5 % of cases each year [12]. How-
ever, this rate may be different from one country to another,
most often because of different criteria for health insurance
system coverage. In France, the rate of bilateral injections
in retinal pathologies is unknown and the use of bevacizu-
mab was off-label regardless of the indication, during the
duration of the survey. Ranibizumab has been authorized
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for the treatment of nAMD, DME, macular edema compli-
cating RVO, CNV complicating pathologic myopia and
pseudoxanthoma elasticum and its use is covered by the
health insurance system. Aflibercept is authorized for the
treatment of nAMD, macular edema complicating central
RVO and DME. Thus, evaluating the burden of intravitreal
injections on French patients is pertinent there is no ad-
ministrative limitation, because the number of intravitreal
injections is not regulated by the healthcare system but only
by the need for treatment. Administrating bilateral same-
day intravitreal injections is becoming more common. In-
deed, a US survey has shown that 46 % of retina specialists
administered bilateral same-day intravitreal injections [13]
limiting the frequent need to access the clinic.
The aim of this study was to estimate the need for bi-
lateral intravitreal anti-VEGF injections in a real-life set-
ting in patients treated for nAMD, DME, RVO, myopic
CNV, and other causes of CNV.
Methods
All consecutive patients who received an intravitreal in-
jection of anti-VEGF over a 1-month period (July 1 to
31, 2014) were included in a prospective multicenter
study. Three centers participated in the study: a private
practice in Paris (Centre d’Imagerie et de Laser), and
two public and academic ophthalmological departments,
one in a Paris hospital (Lariboisière hospital) and one in
a hospital in Paris suburbs (Avicenne hospital). The pri-
vate practice is one of the center performing the largest
number of intravitreal injections in France and both aca-
demic hospitals selected are specialized in DME. The 3
centers are located in a same geographic area. This study
was conducted in accordance with the tenets of the Dec-
laration of Helsinki, and an informed written consent
was obtained from subjects. Approval was obtained from
the France Macula Federation ethical committee (com-
mittee’s reference number: FMF 2015–137).
All data were collected in each center by one of the au-
thors (AGA) and included: the reason for intravitreal injec-
tion of anti-VEGF and the involvement of the fellow eye in
the pathology requiring an intravitreal injection of anti-
VEGF. The number of patients requiring bilateral treat-
ment previously (at any time), within a 1-month interval,
and receiving same-day intravitreal injections was assessed.
Patients were included regardless of the anti-VEGF
drug used. Patients treated with other intravitreal treat-
ments (triamcinolone, dexamethasone implant) were ex-
cluded. Patients injected twice during the study period
(once in one eye, and once in the fellow eye) were only
taken into account once. Sub-group analysis was con-
ducted in patients treated for DME or nAMD in order
to compare the rate of bilateral treatment. A second
sub-analysis was conducted to compare the time interval
between bilateral injections in patients treated for
nAMD and DME.
For statistical analysis, Graphpad prism software was
used and a Chi2 test was performed.
The survey was conducted in accordance with the te-
nets of the Declaration of Helsinki, and an informed
consent was obtained from all patients.
Results
A total of 1335 patients from three ophthalmological cen-
ters were included over a 1-month study period. They re-
ceived a total of 1501 intravitreal anti-VEGF injections.
Among them, 1024 (76.7 %) patients were treated for
nAMD and 167 (12.5 %) for DME. The details of the path-
ologies and the distribution between the three centers are
presented in Table 1. All the data collected are available in
the Additional file 1: Table S1.
Four hundred and fifty-nine (34.4 %) patients were
treated bilaterally with a time interval between injections
longer than 1 month, 170 (12.7 %) were treated bilaterally
within a 1-month period, and 87 (6.6 %) had same-day bi-
lateral injections.
A sub-group analysis was performed in patients treated
for nAMD and DME in order to compare the rate of bilat-
eral treatment. The results are presented in Fig. 1. The
rate of bilateral injections was significantly higher in dia-
betic patients than in nAMD patients (respectively 48 %
vs. 36 %, p = 0.0033).
The time interval between bilateral injections was then
analyzed in patients treated for nAMD and DME (Fig. 2).
In nAMD patients, bilateral injections were administered
on the same day, within a time interval >1 day and <
1 month, and within a time interval longer than 1 month
respectively in 13.8, 19, and 67.2 % of cases. In DME pa-
tients, the distribution was respectively in 42.5, 13.7 and
43.8 % of cases. The number of cases receiving same-day
bilateral treatment was significantly higher in DME pa-
tients than in nAMD patients (respectively 42.5 % vs.
13.8 %, p <0.001). In vein occlusion, bilateral injections
were administered in 2 cases (2.5 %) only, within a time
Table 1 Distribution of the different pathologies requiring anti-
VEGF treatment between the three centers








nAMD 674 (86.6) 269 (66.1) 81 (54) 1024 (76.7)
DME 17 (2.2) 98 (24.1) 52 (34.7) 167 (12.5)
Vein occlusions 44 (5.7) 26 (6.4) 11 (7.3) 81 (6.1)
CNV in high myopic eyes 22 (2.8) 3 (0.7) 6 (4) 31 (2.3)
Others 21 (2.7) 11 (2.7) 0 33 (2.4)
Total 778 (58.3) 407 (30.5) 150 (11.2) 1335 (100)
Raw numbers (percentage)
CNV choroidal neovascularization, DME diabetic macular edema, nAMD
neovascular age-related macular degeneration
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interval longer than 1 month for both. In high myopia,
none of the patient received same-day bilateral injection,
1 patient (3.2 %) received bilateral treatment within a
time interval >1 day and < 1 month, and 5 (6.2 %) within
a time interval longer than 1 month. No case of endoph-
thalmitis was reported.
Discussion
In this study, we estimated the proportion of patients
treated for ocular pathologies with anti-VEGF therapy
and needing bilateral injections over a 1-month period.
Our data show that the rate of bilateral injections was of
36 % in nAMD. Only a few studies have investigated the
rate of bilateral injections in nAMD although a bilateral
involvement in this disease of about 5–20 % per year has
been previously reported [14–19]. In addition, Zarranz-
Ventura et al. [12], have reported an incidence of second
eyes treated with ranibizumab for nAMD of about 7.5 %
per year which increased to 14 % per year when patients
with visual acuity lower than 20/200 in the fellow eye
were excluded. Compared to nAMD, the proportion of
bilateral involvement in DME is higher and estimated to
range between 60 and 80 % [20–22]. Consistently, a sig-
nificantly higher (48 %, p = 0.0033) proportion of bilat-
eral injections in DME patients was found in our study.
This high rate of bilateral involvement in DME could be
due to the systemic nature of disease, making it more
likely to affect both eyes. The discrepancy between the
reported rate of bilateral injections in this study and that
described in nAMD and DME could be explained by the
design of our study. Indeed, the rate of bilateral involve-
ment increases with the follow-up and disease duration
and in this study, it was assessed at a specific time point
(i.e., within a 1-month period).
The time interval between bilateral injections was also
evaluated in this study. In the management of nAMD
patients, there was a tendency to first administer injec-
tion in one eye then followed a few days to a few weeks
later by an injection in the fellow eye. Therefore, only
13.8 % of patients received same-day bilateral injections.
By contrast, the treatment was more often concomitant
in the management of DME patients as 42.5 % of pa-
tients in our study received same-day bilateral injections.
Two parameters could have influenced this proportion.
First, patient preference could have contributed because
one visit for same-day bilateral injections decreases the
burden on patients and their families compared to two
separate visits. Second, bilateral treatment feasibility re-
quires that both eyes are perfectly synchronized and
have the same reactivation time.
Bilateral injections performed the same day when indi-



























Fig. 1 Percentage of patients who received bilateral intravitreal anti-VEGF injections regardless of the time interval between bilateral injections,
showing a significant difference between nAMD and DME (respectively 36 % vs. 48 % of patients, p <0.01)
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limit the frequent visits to the clinic for the patient and
his accompanying persons. When administering same-day
bilateral intravitreal injections, local and systemic complica-
tions should be considered. Local complications of intravit-
real injections include raised intraocular pressure, uveitis,
retinal detachment and subretinal hemorrhages [23]. Retro-
spective studies have investigated the safety of same-day bi-
lateral intravitreal injections and shown that when separate
povidone-iodine preparations, speculum, needles, and sy-
ringes are used for each eye, injections are well tolerated
[24, 25]. In the review by Lima et al. [26], it has been sug-
gested that the ocular complications (endophthalmitis and
intraocular inflammation) related to same-day bilateral in-
travitreal injections are similar to those appearing after uni-
lateral injections [26]. None was reported in our study.
Although rare, systemic side effects of intravitreal anti-
VEGF treatment have also been reported, including myo-
cardial infarctions, strokes and thromboembolic events
[27]. However, it remains unknown whether an increase in
systemic dose due to bilateral injections may increase the
risk. Several studies have evaluated the outcomes and com-
plications of same-day bilateral intravitreal injections and
no major systemic events have been reported [28, 29]. The
present survey was not designed to give any information
concerning local or systemic tolerance of anti-VEGF drugs
administrated the same day. The main limitation of our
study is its descriptive nature and the limited data on pa-
tient characteristics and history of ocular diseases. However,
our results provide relevant data in a real-world setting by
evaluating the frequency of bilateral intravitreal anti-VEGF
injections administered by French retina specialists in pa-
tients treated for retinal pathologies.
Conclusion
Efficacy and safety outcomes of bilateral anti-VEGF in-
jections have been recently studied.
As the rate of second eye involvement requiring treat-
ment increases progressively over time, a same-day bi-
lateral injection strategy will become more common as
it decreases the administrative burden on the health-
care system and the treatment burden experienced by
patients and families.
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Fig. 2 Distribution of the time interval between bilateral injections in nAMD and DME patients. Same-day bilateral injections were significantly
more common in DME patients than in nAMD patients (respectively 42.5 % vs. 13.8 %, p <0.001)
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